Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy

Lancet Neurol. 2017 Feb;16(2):104-106. doi: 10.1016/S1474-4422(16)30382-9.

Authors

Aiden Haghikia¹, Calliope A Dendrou², Ruth Schneider¹, Thomas Grüter¹, Thomas Postert³, Mike Matzke⁴, Heike Stephanik⁴, Lars Fugger², Ralf Gold⁵

Affiliations

¹ Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany.
² Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences and MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
³ Neurologic Clinic, St Vincenz-Krankenhaus, Paderborn, Germany.
⁴ Department of Neurology of the University of Magdeburg, Magdeburg, Germany.
⁵ Department of Neurology of the Ruhr-University Bochum at St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany. Electronic address: [email protected].

PMID: 28102146
DOI: 10.1016/S1474-4422(16)30382-9

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Alemtuzumab / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
B-Lymphocytes* / immunology
Brain / diagnostic imaging*
Brain / drug effects*
Brain / immunology
Central Nervous System Diseases / chemically induced
Central Nervous System Diseases / diagnostic imaging
Central Nervous System Diseases / immunology
Female
Humans
Male
Multiple Sclerosis / diagnostic imaging
Multiple Sclerosis / drug therapy
Multiple Sclerosis / immunology
Severity of Illness Index*

Substances

Antineoplastic Agents, Immunological
Alemtuzumab

Grants and funding

100308/Wellcome Trust/United Kingdom